Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Article
[키워드] 95% CI
95% confidence interval
acute respiratory syndrome
addition
Administered
Analysis
attenuation
BNT162b2
Breakthrough infection
Care
center
circulation
conditions
conducted
Control
coronavirus
coronavirus disease
dose
duration of illness
effective
Effectiveness
febrile
febrile symptom
hazard ratio
Health
Infection
Local
Messenger RNA
Moderna
mRNA
mRNA vaccine
mRNA-1273
nasal swab
participant
Participants
participants with SARS-CoV-2
Pfizer-BioNTech
preventing infection
prevention
prospective cohort study
Quantitative
respiratory
responders
risk
RT-PCR
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 testing
sick
Symptoms
the mean
the vaccine
vaccination
Vaccine
viral RNA load
were excluded
[DOI] 10.1056/NEJMoa2107058 PMC 바로가기 [Article Type] Article
[DOI] 10.1056/NEJMoa2107058 PMC 바로가기 [Article Type] Article